RxDoctor Payments Data

Richa Pandey, MD

Nephrology · Springfield, ILNPI 1922312834

Payments from drug & device makers

$575in general payments, 2019–2025

Across 22 payments — averaging $26.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$152
  • Amgen$90
  • Alnylam Pharmaceuticals Inc.$75
  • Otsuka America Pharmaceutical, Inc.$61
  • Akebia Therapeutics Inc$43
  • Calliditas Therapeutics US Inc.$35
  • plus $118 from 5 others

What the payments were for

  • Food & beverage$46481%
  • Education$11119%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$575 in reported general payments places this provider in the 45th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$267,362
Medicare patients
870
Services billed
3,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan20$396,103
FarxigaDapagliflozin Propanediol184$141,131
JardianceEmpagliflozin149$103,691
VelphoroSucroferric Oxyhydroxide20$91,935
AuryxiaFerric Citrate23$34,216
Lanthanum Carbonate15$32,236
LokelmaSodium Zirconium Cyclosilicate75$31,780
VeltassaPatiromer Calcium Sorbitex26$25,180
Sevelamer Carbonate82$16,242
Cyclosporine12$10,718
Potassium Chloride262$8,923
Potassium Citrate ErPotassium Citrate93$7,096
Paricalcitol23$3,230
Torsemide143$2,740
Furosemide720$2,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$61$396,10320 claims
Boehringer IngelheimJardiance$26$103,691149 claims
Fresenius USA Marketing, Inc.Velphoro$19$91,93520 claims
Akebia Therapeutics IncAuryxia$43$34,21623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 524 nephrology providers in Illinois.

Other nephrology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →